NICE upholds GSK appeal for advanced breast cancer treatment, Tyverb® (lapatinib)

NICE upholds GSK appeal for advanced breast cancer treatment, Tyverb® (lapatinib)

- NICE will reconsider the evidence supporting lapatinib

The National Institute for Health and Clinical Excellence (NICE) today announced that, following GlaxoSmithKline's (GSK) appeal, it will reconsider the submission for Tyverb (lapatinib), a treatment for an aggressive form of advanced breast cancer (ErbB2-positive).1 GSK is pleased that NICE's appeal panel agreed that the draft negative guidance should be reviewed, providing fresh hope for up to 2,000 women in the UK who could benefit from this effective treatment on the NHS.

Dr Alison Jones, Medical Oncologist at the University College London Hospital and the Royal Free Hospital commented: "It is great that NICE will reconsider the evidence supporting the use of lapatinib as there is a significant unmet medical need for women with this aggressive form of advanced breast cancer. These women have very few treatment options left available to them and lapatinib, when combined with capecitabine, offers a chance of additional time without their disease progressing."

The appeal has been upheld in light of new supplementary NICE advice for the assessment of treatments in small patient populations with a short life expectancy, issued in January this year.2 The appeal panel agreed that GSK and other consultees should be given the opportunity to make a full submission under these new ‘end of life' criteria.1

Simon Jose, General Manager, GSK UK commented: "We welcome the decision of the appeal panel and the opportunity to make a full submission to NICE under the end of life criteria. We appreciate that NICE has some very tough decisions to make, especially in this end of life setting, but given the considerable survival benefits that Tyverb offers these women, we believe it deserves full and thorough consideration."

In line with previous commitments, GSK UK will continue to offer the Tyverb Patient Access Programme to both NICE and individual NHS Trusts. Under this scheme GSK bears the cost of lapatinib for up to the first 12 weeks of treatment,
Safety Information:

Lapatinib plus capecitabine is generally well tolerated. The most common adverse events associated with lapatinib plus capecitabine were diarrhoea, rash, nausea, vomiting, fatigue and hand-foot syndrome.3,4 Diarrhoea and rash were more common with the combination whilst the incidence of hand-foot syndrome was similar between the two treatment groups.3 A decrease in left ventricular ejection fraction (LVEF) was reported by 2.5% of patients receiving lapatinib plus capecitabine vs. 1% of patients on capecitabine alone.3 Hepatobiliary events (mainly raised liver enzymes and/or bilirubin levels) have been reported commonly in association with lapatinib plus capecitabine therapy.3 Lapatinib has also been associated with reports of pulmonary toxicity.

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.